Oops! You got it wrong...
EXPLANATION
✔Correct answer:
Lithium and demeclocycline. Nephrogenic diabetes insipidus (NDI) occurs when the renal tubules do not respond to antidiuretic hormone (ADH), leading to the inability of the kidneys to concentrate urine, resulting in the excretion of large volumes of dilute urine. This condition can be induced by certain medications that interfere with the kidney's response to ADH.
Lithium and demeclocycline are well-known to potentially cause nephrogenic diabetes insipidus. Lithium, used in the treatment of bipolar disorder, can affect the kidney's ability to concentrate urine by interfering with the action of ADH on the renal tubules. Demeclocycline, a tetracycline antibiotic, can similarly antagonize the effects of ADH, leading to a decreased ability of the kidneys to concentrate urine.
Imagine the kidney's ability to concentrate urine as a garden hose with an adjustable nozzle at the end, where the nozzle controls how much water is let out. ADH acts like the mechanism that tightens the nozzle, reducing the flow of water to ensure that only a small, concentrated amount is released, which conserves water in the body.
When medications like lithium and demeclocycline are introduced, it's as if they're interfering with the nozzle's adjustment mechanism, preventing it from tightening properly. As a result, the hose continues to let out water more freely than it should, leading to an increased production of dilute urine, akin to the excessive water loss seen in nephrogenic diabetes insipidus.
ADH plays a critical role in water balance by promoting water reabsorption in the kidneys' collecting ducts, thus concentrating the urine. It does this by binding to V2 receptors on the renal tubules, which in turn stimulates the insertion of aquaporin-2 channels into the tubule cells, allowing water to be reabsorbed back into the bloodstream. Lithium interferes with the signaling pathway downstream of the V2 receptor, preventing the normal action of ADH. Demeclocycline is thought to impair the renal tubule's response to ADH by a similar mechanism, though its exact action is less well understood.
✘Incorrect answer options:
Bromocriptine and cabergoline. These drugs are dopamine agonists used primarily in the treatment of Parkinson’s disease and prolactinomas. They do not typically affect the renal response to ADH in a way that leads to nephrogenic diabetes insipidus.
Cimetidine and verapamil. Cimetidine is a histamine H2 receptor antagonist used to treat peptic ulcers, and verapamil is a calcium channel blocker used in the management of hypertension and cardiac arrhythmias. Neither is commonly associated with causing nephrogenic diabetes insipidus.
Hydrochlorothiazide and furosemide. These are diuretic medications used to treat fluid overload conditions and hypertension. While they increase urine production, they do not typically induce nephrogenic diabetes insipidus by antagonizing the effects of ADH on the renal tubules. In fact, hydrochlorothiazide can be used as part of the treatment for nephrogenic diabetes insipidus by inducing a mild volume depletion, which increases proximal sodium and water reabsorption, thus reducing polyuria.
References
- Rose, B. D., & Post, T. W. (2019). Clinical Physiology of Acid-Base and Electrolyte Disorders. McGraw-Hill Education. This book provides insights into the mechanisms of action of various drugs on renal function, including those that can cause nephrogenic diabetes insipidus.
- Schrier, R. W. (2017). Diseases of the Kidney and Urinary Tract. Wolters Kluwer Health. This comprehensive resource covers the pathophysiology and management of renal diseases, including drug-induced nephrogenic diabetes insipidus.